Everything below concerns Somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
=== Available forms === Ceftriaxone is available for administration via the intramuscular or the intravenous routes. Ceftriaxone is stored as a dry powder in a vial, and is reconstituted (dissolved) immediately before use. The solution is used promptly after preparation, still, reconstituted solutions retain their physical and chemical stability for 24 hours at 25°C (or for 3 days when stored between 2 and 8°C). The solutions are pale yellowish in color, but the change of color to amber or reddish suggests hydrolysis of the amide bond of the β-lactam ring, thereby affecting the antimicrobial activity of the antibiotic. Diluents containing calcium are not used to reconstitute ceftriaxone, and it must not be administered in intravenous lines containing other calcium-containing solutions, as a ceftriaxone-calcium precipitate could form. This precipitation risk is particularly high in newborns (up to age 28 days), especially if they are premature or have impaired bilirubin binding. Beyond the approved intramuscular and intravenous routes, ceftriaxone has also been administered off-label via the subcutaneous route. This practice has been reported in multiple clinical series, particularly in elderly, frail, or palliative-care patients and in those with difficult venous access. Pharmacokinetic data and clinical observations suggest that subcutaneous ceftriaxone provides adequate systemic exposure and is generally well tolerated, with reported clinical effectiveness comparable to intravenous administration in selected, non–critically ill patients.
Harvest stagnation in wild fisheries and overexploitation of popular marine species, combined with a growing demand for high-quality protein, encouraged aquaculturists to domesticate other marine species. At the outset of modern aquaculture, many were optimistic that a "Blue Revolution" could take place in aquaculture, just as the Green Revolution of the 20th century had revolutionized agriculture. Although land animals had long been domesticated, most seafood species were still caught from the wild. Concerned about the impact of growing demand for seafood on the world's oceans, prominent ocean explorer Jacques Cousteau wrote in 1973: "With earth's burgeoning human populations to feed, we must turn to the sea with new understanding and new technology." About 430 (97%) of the species cultured as of 2007 were domesticated during the 20th and 21st centuries, of which an estimated 106 came in the decade to 2007. Given the long-term importance of agriculture, to date, only 0.08% of known land plant species and 0.0002% of known land animal species have been domesticated, compared with 0.17% of known marine plant species and 0.13% of known marine animal species. Domestication typically involves about a decade of scientific research. Domesticating aquatic species involves fewer risks to humans than do land animals, which took a large toll in human lives. Most major human diseases originated in domesticated animals, including diseases such as smallpox and diphtheria, that like most infectious diseases, move to humans from animals.
In April 1805, Britain and Russia signed a treaty with the aim of removing the French from the Batavian Republic (roughly present-day Netherlands) and the Swiss Confederation. Austria joined the alliance after the annexation of Genoa (Ligurian Republic) and the proclamation of Napoleon as King of Italy on 17 March 1805. Sweden, which had already agreed to lease Swedish Pomerania as a military base for British troops against France, entered the coalition on 9 August. The Austrians began the war by invading Bavaria on 8 September 1805 with an army of about 72,000 under Karl Mack von Leiberich, and the French army marched out from Boulogne in late July 1805 to confront them. At Ulm (25 September – 20 October) Napoleon surrounded Mack's army, forcing its surrender without significant losses. With the main Austrian army north of the Alps defeated (another army under Archduke Charles fought against André Masséna's French army in Italy), Napoleon occupied Vienna on 13 November. Far from his supply lines, he faced a larger Austro–Russian army under the command of Mikhail Kutuzov, with Emperor Alexander I of Russia personally present. On 2 December, Napoleon crushed the Austro–Russian force in Moravia at Austerlitz (usually considered his greatest victory). He inflicted 25,000 casualties on a numerically superior enemy army while sustaining fewer than 7,000 in his own force.
== Research == Specific medications that may reduce the risk or progression of Alzheimer's disease include those that impact Aβ plaques, inflammation, APOE, neurotransmitter receptors, neurogenesis, growth factors or hormones. Machine learning algorithms with electronic health records are studied as a way to predict Alzheimer's disease earlier. As of 2025, 182 clinical trials were testing 138 drugs against multiple targets.
=== From primary cancer to the meninges === NM is a secondary cancer meaning that it is the result of neoplastic cells that have metastasized from a primary cancer site. These cancers develop an enzyme that is able to break down blood vessels at a microscopic level. These cells enter the blood vessels and travel across the body. Once the brain is reached, they break down the blood–brain barrier to enter the Cerebrospinal Fluid (CSF). There the cancerous cells seed and disseminate into the leptomeninges which are composed of the arachnoid and the pia. The CSF continues to carry neoplastic cells through the brain tracts and spreads the cancerous cells. Lung cancer, breast cancer, and melanoma comprise the majority of solid tumors spreading to the leptomeninges. Although rare, meningeal carcinomatosis can arise from cervical cancer. Only eight cases of MC arising from squamous cell carcinoma of the uterine cervix are previously reported in the literature. Since NM is a result of primary cancer metastasis and can develop from primary brain tumors or parenchymal metastasis when tumor cells are lodged in small central nervous system (CNS) vasculature, causing local ischemia and vessel damage which result in tumor spillage into the Virchow-Robin spaces and providing access to the subarachnoid space.
Sources: en.wikipedia.org
Sensory neurons (afferent): Relay sensory information in the form of an action potential (nerve impulse) from the PNS to the CNS Motor neurons (efferent): Relay an action potential out of the CNS to the proper effector (muscles, glands) Interneurons: Cells that form connections between neurons and whose processes are limited to a single local area in the brain or spinal cord Structural classification:
=== Social media and memes === On X (formerly Twitter), there are numerous accounts with names like "Socialists for Pritzker", "Nomadic Warriors for Pritzker", "Frat Bros for Pritzker", and "Anarchists for Pritzker". Socialists for Pritzker has over 13,000 followers. The accounts have been described as semi-ironic. Pritzker has said the attention is "entertaining, if a little strange" and that he keeps up with several of the accounts. Nomadic Warriors for Pritzker has dubbed Pritzker the "Great Khan of the Midwest" and mapped out battle plans for a Mongol Empire-inspired military campaign across the nation. The group of accounts, dubbed the "Pritzker Pals", launched a website, coconutbigboy.com, with the goal of influencing Vice President Kamala Harris to pick Pritzker as her running mate in the 2024 presidential election. A TikTok account called "Pritzker Memes" garnered 20,000 followers. Some of the memes relate to Pritzker's size, with one political commentator saying, "He is enormous, doesn't come off as particularly intellectual, and has good instincts". Pritzker launched his own beer brand, JBeers, ahead of the 2024 Democratic National Convention in Chicago. He also named Malört the DNC's "unofficial shot". On February 7, 2025, after President Trump announced that the Gulf of Mexico had been renamed the "Gulf of America", Pritzker posted a satirical video on his personal Twitter account announcing Illinois's annexation of Green Bay, Wisconsin, and the renaming of Lake Michigan to "Lake Illinois".
=== Mortality === Published studies on the survival of Sjögren's disease patients have been limited in various respects, perhaps owing to the relatively small sample sizes and the fact that secondary Sjögren's disease is associated with other autoimmune diseases. A 2010 study found a slight increase in mortality rates of Sjögren's patients compared with the remainder of the population. A 2016 study found that primary Sjögren's was not associated with an increase in all-cause mortality as compared with the general population, but that a subset of patients with extraglandular involvement, vasculitis, hypocomplementaemia, and cryoglobulinaemia may be at increased risk of mortality. A 2021 metaanalysis showed a 46% increase in mortality, with significantly greater mortality risk in patients with older age, male gender, vasculitis, interstitial lung disease, low complements, positive anti-La/SSB and cryoglobulinaemia. Among those without other autoimmune disorders, life expectancy is unchanged.
Bone is a rigid organ that constitutes part of the vertebral skeleton. Bones support and protect the various organs of the body, produce red and white blood cells, store minerals and also enable mobility. Bone tissue is a type of dense connective tissue. Bones come in a variety of shapes and sizes and have a complex internal and external structure. They are lightweight yet strong and hard, and serve multiple functions. Mineralized osseous tissue or bone tissue, is of two types – cortical and cancellous and gives it rigidity and a coral-like three-dimensional internal structure. Other types of tissue found in bones include marrow, endosteum, periosteum, nerves, blood vessels and cartilage. Bone is an active tissue composed of different cells. Osteoblasts are involved in the creation and mineralisation of bone; osteocytes and osteoclasts are involved in the reabsorption of bone tissue. The mineralised matrix of bone tissue has an organic component mainly of collagen and an inorganic component of bone mineral made up of various salts.
Sources: en.wikipedia.org
Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. In 2017 GSK announced Albiglutide's withdrawal from the worldwide market for economic reasons, and remaining stocks in the supply chain were effectively depleted by 2018. Albiglutide was used for the treatment of type 2 diabetes in adults. It can be used alone (if metformin therapy is ineffective or not tolerated) or in combination with other antidiabetic drugs, including insulins. According to a 2015 analysis, albiglutide is less effective than other GLP-1 agonists for lowering glycated hemoglobin (HbA1c, an indicator for long-term blood glucose control) and weight loss. It also seems to have fewer side effects than most other drugs of this class, except for reactions at the injection site which are more common under albiglutide than, for example, under liraglutide.
Fourteen isotopes of lawrencium are known, with mass number 251–262, 264, and 266; all are radioactive. Seven nuclear isomers are known. The longest-lived isotope, 266Lr, has a half-life of about ten hours and is one of the longest-lived superheavy isotopes known. However, shorter-lived isotopes are usually used in chemical experiments because 266Lr can only be produced as a final decay product of even heavier and harder-to-make elements: it was discovered in 2014 in the decay chain of 294Ts. 256Lr (half-life 27 seconds) was used in the first chemical studies on lawrencium: the longer-lived 260Lr (half-life 2.7 minutes) is usually used for this purpose. After 266Lr, the longest-lived isotopes are 264Lr (4.8+2.2−1.3 h), 262Lr (3.6 h), and 261Lr (44 min). All other known lawrencium isotopes have half-lives under 5 minutes, and the shortest-lived of them (251Lr) has a half-life of 24.4 milliseconds. The half-lives of lawrencium isotopes mostly increase smoothly from 251Lr to 266Lr, with a dip from 257Lr to 259Lr.
Half & Half is an American television sitcom created by Jeffrey Klarik and executive-produced by Yvette Lee Bowser through her Sister Lee Productions banner that aired on UPN from September 23, 2002, to May 15, 2006 (related to the Fox comedy show, Living Single that aired out in 1993 until 1998). It was co-produced by CBS Studios under one of its former aliases, Eye Productions, Inc. Set in San Francisco, California, the show centers on the lives of two paternal half-sisters in their early adulthood who were estranged throughout their childhood, and are finally developing a close relationship. The show was the second-most-watched on UPN's Monday night line-up (next to Girlfriends) and fourth overall on the network. The series was almost renewed for a fifth season by UPN's successor network, The CW, but due to several circumstances — including the network's contractual obligation to pick up Reba, the last-minute renewal of All of Us, and the pick-up of the Girlfriends spin-off The Game — the series was left off the network's Autumn 2006 schedule and canceled. Outside of the United States, the series has aired in reruns on Global TV in Canada, Trouble in the United Kingdom and in local syndication channels in the United States, including Bounce TV, TV One, Cleo TV, BET Her and Dabl. The series is available to stream on Paramount+ and Amazon Prime Video.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.